FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556682271> ?p ?o ?g. }

• W2556682271 abstract "Abstract Abstract 699 Background: Combination immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) gave superior progression free and overall survival compared to FC in the German CLL8 Study. The median age in CLL8 was 61 years compared to a median age for overall CLL patients of 72 years. There is ongoing debate regarding the tolerability and safety of FCR in elderly patients. Arbitrary dose reductions are common practice. Oral FC is more convenient for many older patients. Methods: Previously untreated patients with progressive CLL aged ≥65 were randomised to one of three treatment regimens FR5, FCR3 and FCR5 as follows: (i) F 24mg/m2 po D1-5 + R (375 mg/m2 C1, 500mg/m2 C2-6) iv D1 (FR5), (ii) F 24mg/m2 po and C 150mg/m2 po D1-3 + R iv D1 (FCR3) or (iii) F 24mg/m2 po + C 150mg/m2 po D1-5 + R iv D1 (FCR5), all given at monthly intervals for an intended 6 cycles. The dosage of FCR5 is equivalent to standard intravenous FCR in the CLL8 Study. Patients were administered their therapy arm with no dose reduction. Fludarabine dosing was reduced according to renal function by calculated GFR. Therapy was delayed by 2 weeks if there was any grade 3 or 4 toxicity. If this was unresolved after 2 weeks, patients were taken off study. If toxicity resolved to grade 2 or less, therapy proceeded. Results: Over half the planned patients (65 of 120) were recruited by 1 August, 2010 from 21 centres in Australia and New Zealand with the study having been open for 18 months. Median age is 72 (range 65–85) years. Binet stage at registration was progressive A – 11 (16.9%), B – 32 (49.2%) and C – 22 (33.8%). Randomisations are FR5 – 22, FCR3 – 22 and FCR5 – 21. FISH data is available on 50 patients: 25 with 13q-, 9 with 12+, 4 with 11q−, and 6 with 17p−. P53 functional analysis is available on 15 patients. Interim reasons for cessation of treatment, dose delay and clinical responses are shown in tables 1, 2 and 3 respectively for the total patient cohort. Cessations for reasons other than toxicity occurred in 7 patients: intercurrent illness (N=2) with acute myocardial infarction (AMI) and recurrent episodes of amnesia, and other reasons (N=5). Deaths were recorded for 2 patients due to infection and AMI. Conclusions: Oral F(C)R therapy appears generally safe and well tolerated to date in CLL patients aged ≥65 years requiring first-line treatment. Using stringent stopping criteria with delay of 2 weeks for recovery of grade 3 or 4 toxicity but no dose reduction, about half the patients will stop early due to toxicity or intercurrent illness. Nevertheless, response rates are high. Accrual is ongoing. Disclosures: Mulligan: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer Schering, now Genzyme: Honoraria. Seymour:Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau." @default.
• W2556682271 created "2016-11-30" @default.
• W2556682271 creator A5002467749 @default.
• W2556682271 creator A5012712238 @default.
• W2556682271 creator A5027054405 @default.
• W2556682271 creator A5038930768 @default.
• W2556682271 creator A5045706969 @default.
• W2556682271 creator A5081326206 @default.
• W2556682271 creator A5087985272 @default.
• W2556682271 date "2010-11-19" @default.
• W2556682271 modified "2023-09-30" @default.
• W2556682271 title "The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study." @default.
• W2556682271 doi "https://doi.org/10.1182/blood.v116.21.699.699" @default.
• W2556682271 hasPublicationYear "2010" @default.
• W2556682271 type Work @default.
• W2556682271 sameAs 2556682271 @default.
• W2556682271 citedByCount "6" @default.
• W2556682271 countsByYear W25566822712012 @default.
• W2556682271 countsByYear W25566822712013 @default.
• W2556682271 crossrefType "journal-article" @default.
• W2556682271 hasAuthorship W2556682271A5002467749 @default.
• W2556682271 hasAuthorship W2556682271A5012712238 @default.
• W2556682271 hasAuthorship W2556682271A5027054405 @default.
• W2556682271 hasAuthorship W2556682271A5038930768 @default.
• W2556682271 hasAuthorship W2556682271A5045706969 @default.
• W2556682271 hasAuthorship W2556682271A5081326206 @default.
• W2556682271 hasAuthorship W2556682271A5087985272 @default.
• W2556682271 hasConcept C126322002 @default.
• W2556682271 hasConcept C141071460 @default.
• W2556682271 hasConcept C197934379 @default.
• W2556682271 hasConcept C2776694085 @default.
• W2556682271 hasConcept C2776755627 @default.
• W2556682271 hasConcept C2778375690 @default.
• W2556682271 hasConcept C2779263901 @default.
• W2556682271 hasConcept C2779338263 @default.
• W2556682271 hasConcept C2780653079 @default.
• W2556682271 hasConcept C29730261 @default.
• W2556682271 hasConcept C535046627 @default.
• W2556682271 hasConcept C61943457 @default.
• W2556682271 hasConcept C71924100 @default.
• W2556682271 hasConcept C90924648 @default.
• W2556682271 hasConceptScore W2556682271C126322002 @default.
• W2556682271 hasConceptScore W2556682271C141071460 @default.
• W2556682271 hasConceptScore W2556682271C197934379 @default.
• W2556682271 hasConceptScore W2556682271C2776694085 @default.
• W2556682271 hasConceptScore W2556682271C2776755627 @default.
• W2556682271 hasConceptScore W2556682271C2778375690 @default.
• W2556682271 hasConceptScore W2556682271C2779263901 @default.
• W2556682271 hasConceptScore W2556682271C2779338263 @default.
• W2556682271 hasConceptScore W2556682271C2780653079 @default.
• W2556682271 hasConceptScore W2556682271C29730261 @default.
• W2556682271 hasConceptScore W2556682271C535046627 @default.
• W2556682271 hasConceptScore W2556682271C61943457 @default.
• W2556682271 hasConceptScore W2556682271C71924100 @default.
• W2556682271 hasConceptScore W2556682271C90924648 @default.
• W2556682271 hasLocation W25566822711 @default.
• W2556682271 hasOpenAccess W2556682271 @default.
• W2556682271 hasPrimaryLocation W25566822711 @default.
• W2556682271 hasRelatedWork W126125533 @default.
• W2556682271 hasRelatedWork W1990815726 @default.
• W2556682271 hasRelatedWork W2140606816 @default.
• W2556682271 hasRelatedWork W2142099365 @default.
• W2556682271 hasRelatedWork W2326926256 @default.
• W2556682271 hasRelatedWork W2347546609 @default.
• W2556682271 hasRelatedWork W2348637346 @default.
• W2556682271 hasRelatedWork W2462429923 @default.
• W2556682271 hasRelatedWork W2485364093 @default.
• W2556682271 hasRelatedWork W2513699174 @default.
• W2556682271 hasRelatedWork W2522069870 @default.
• W2556682271 hasRelatedWork W2533912613 @default.
• W2556682271 hasRelatedWork W2551251624 @default.
• W2556682271 hasRelatedWork W2559761794 @default.
• W2556682271 hasRelatedWork W2561271498 @default.
• W2556682271 hasRelatedWork W2587549223 @default.
• W2556682271 hasRelatedWork W2912434766 @default.
• W2556682271 hasRelatedWork W2979701399 @default.
• W2556682271 hasRelatedWork W3109434564 @default.
• W2556682271 hasRelatedWork W348256843 @default.
• W2556682271 isParatext "false" @default.
• W2556682271 isRetracted "false" @default.
• W2556682271 magId "2556682271" @default.
• W2556682271 workType "article" @default.